AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 239 filers reported holding AMICUS THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,046,700 | -13.3% | 250,551 | -10.5% | 0.01% | 0.0% |
| Q2 2023 | $3,515,054 | +10.2% | 279,861 | -2.7% | 0.01% | 0.0% |
| Q1 2023 | $3,190,748 | -10.9% | 287,714 | -1.9% | 0.01% | -16.7% |
| Q4 2022 | $3,579,325 | +18.3% | 293,147 | +1.2% | 0.01% | +20.0% |
| Q3 2022 | $3,025,000 | -5.3% | 289,708 | -2.6% | 0.01% | 0.0% |
| Q2 2022 | $3,193,000 | +11.1% | 297,293 | -2.1% | 0.01% | +25.0% |
| Q1 2022 | $2,874,000 | -23.2% | 303,518 | -6.3% | 0.00% | 0.0% |
| Q4 2021 | $3,742,000 | +23.9% | 323,960 | +2.5% | 0.00% | 0.0% |
| Q3 2021 | $3,019,000 | -13.6% | 316,116 | -12.8% | 0.00% | 0.0% |
| Q2 2021 | $3,494,000 | -9.1% | 362,440 | -6.8% | 0.00% | -20.0% |
| Q1 2021 | $3,844,000 | -57.2% | 389,025 | -0.1% | 0.01% | -61.5% |
| Q4 2020 | $8,990,000 | +65.4% | 389,346 | +1.2% | 0.01% | +44.4% |
| Q3 2020 | $5,434,000 | -6.0% | 384,863 | +0.4% | 0.01% | -10.0% |
| Q2 2020 | $5,781,000 | +60.9% | 383,367 | -1.4% | 0.01% | +25.0% |
| Q1 2020 | $3,593,000 | -5.6% | 388,888 | -0.5% | 0.01% | +33.3% |
| Q4 2019 | $3,807,000 | +19.0% | 390,815 | -2.0% | 0.01% | 0.0% |
| Q3 2019 | $3,198,000 | -28.1% | 398,710 | +11.8% | 0.01% | -33.3% |
| Q2 2019 | $4,450,000 | +12.9% | 356,543 | +23.0% | 0.01% | +12.5% |
| Q1 2019 | $3,942,000 | +38.9% | 289,837 | -2.2% | 0.01% | +33.3% |
| Q4 2018 | $2,838,000 | -18.9% | 296,282 | +2.3% | 0.01% | -14.3% |
| Q3 2018 | $3,501,000 | -22.6% | 289,601 | -0.0% | 0.01% | -22.2% |
| Q2 2018 | $4,525,000 | +6.0% | 289,703 | +2.0% | 0.01% | 0.0% |
| Q1 2018 | $4,270,000 | +12.7% | 283,912 | +7.9% | 0.01% | +12.5% |
| Q4 2017 | $3,788,000 | -5.1% | 263,224 | -0.5% | 0.01% | -11.1% |
| Q3 2017 | $3,990,000 | +55.9% | 264,569 | +4.1% | 0.01% | +80.0% |
| Q2 2017 | $2,560,000 | +27.9% | 254,229 | -9.4% | 0.01% | +25.0% |
| Q1 2017 | $2,001,000 | +37.2% | 280,638 | -4.4% | 0.00% | +33.3% |
| Q4 2016 | $1,458,000 | -34.6% | 293,438 | -2.7% | 0.00% | -40.0% |
| Q3 2016 | $2,231,000 | +53.0% | 301,538 | +12.9% | 0.01% | +66.7% |
| Q2 2016 | $1,458,000 | -29.7% | 267,038 | +8.8% | 0.00% | -25.0% |
| Q1 2016 | $2,075,000 | -0.4% | 245,513 | +14.3% | 0.00% | -20.0% |
| Q4 2015 | $2,083,000 | -29.6% | 214,743 | +1.6% | 0.01% | -37.5% |
| Q3 2015 | $2,957,000 | +18.7% | 211,400 | +20.0% | 0.01% | +33.3% |
| Q2 2015 | $2,492,000 | -20.8% | 176,100 | -39.1% | 0.01% | -14.3% |
| Q1 2015 | $3,148,000 | +2685.8% | 289,334 | +428.3% | 0.01% | – |
| Q1 2014 | $113,000 | -12.4% | 54,764 | 0.0% | 0.00% | – |
| Q4 2013 | $129,000 | +1.6% | 54,764 | 0.0% | 0.00% | – |
| Q3 2013 | $127,000 | +3.3% | 54,764 | +3.3% | 0.00% | – |
| Q2 2013 | $123,000 | -25.9% | 52,996 | +1.3% | 0.00% | -100.0% |
| Q1 2013 | $166,000 | – | 52,294 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |